Sands Capital Alternatives LLC Increases Stake in Inhibikase Therapeutics, Inc. $IKT

Sands Capital Alternatives LLC grew its stake in shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) by 18.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,018,965 shares of the company’s stock after buying an additional 2,068,965 shares during the period. Inhibikase Therapeutics accounts for approximately 5.1% of Sands Capital Alternatives LLC’s portfolio, making the stock its 4th largest holding. Sands Capital Alternatives LLC owned approximately 0.17% of Inhibikase Therapeutics worth $26,689,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets increased its position in shares of Inhibikase Therapeutics by 70.3% during the third quarter. BNP Paribas Financial Markets now owns 15,640 shares of the company’s stock valued at $25,000 after buying an additional 6,458 shares during the period. Sanctuary Advisors LLC bought a new position in shares of Inhibikase Therapeutics in the fourth quarter worth approximately $26,000. JPMorgan Chase & Co. bought a new position in shares of Inhibikase Therapeutics in the second quarter worth approximately $56,000. Invesco Ltd. bought a new position in shares of Inhibikase Therapeutics in the second quarter worth approximately $60,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Inhibikase Therapeutics in the second quarter worth approximately $64,000. 3.81% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IKT has been the topic of several research analyst reports. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Tuesday, April 21st. Oppenheimer initiated coverage on shares of Inhibikase Therapeutics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $5.00 price objective on the stock. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Inhibikase Therapeutics in a research report on Wednesday, March 4th. They issued a “buy” rating and a $4.00 price objective on the stock. Four analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Inhibikase Therapeutics presently has a consensus rating of “Buy” and an average price target of $5.40.

Inhibikase Therapeutics Stock Performance

IKT stock opened at $1.67 on Monday. The stock has a market cap of $220.49 million, a price-to-earnings ratio of -3.88 and a beta of 0.93. The company’s 50 day moving average is $1.77 and its 200 day moving average is $1.75. Inhibikase Therapeutics, Inc. has a 1-year low of $1.33 and a 1-year high of $2.26.

Inhibikase Therapeutics (NASDAQ:IKT) last issued its earnings results on Tuesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). As a group, sell-side analysts forecast that Inhibikase Therapeutics, Inc. will post -0.4 EPS for the current fiscal year.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.